SEARCH OUR PAGES

OSE Immunotherapeutics,
a clinical-stage biotechnology company

focused on developing and partnering therapies to control the immune system
for immuno-oncology and autoimmmune diseases.

4

Products in clinical-stage status

2

Partnerships with international pharma companies

30

High-level collaborators

Collaborations and partnerships

A fundamental element of both long-term strategy and day-to-day operations

A clinical-stage biotechnology company in immunotherapy

  • Scientific and Technological
    Platforms

    Neoepitopes,
    agonist or antagonist monoclonal antibodies

    +
  • Immuno-oncology

    T-cell activation through neoepitopes
    Transforming tumor microenvironment
    suppressive cells into effector cells

    +
  • Autoimmune Diseases

    Down regulating T effector cells to decrease immunological reactivity

    Up regulating regulatory
    T-cells to develop immune tolerance

    +
  • Partnerships

    Premier international pharma, clinical and academic collaborations to speed up the delivery of our product candidates to patients in need

    +

Latest news

OSE Immunotherapeutics Regains Worldwide Rights…

DISCOVER +

OSE Immunotherapeutics Presents Selective SIRP-alpha…

DISCOVER +

OSE Immunotherapeutics Announces Publication in…

DISCOVER +

OSE Immunotherapeutics and Oncology Physician…

DISCOVER +

To receive OSE Immunotherapeutics’ latest news


SUBMIT

You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links or by contacting us at contact@ose-immuno.com